{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:30:16Z","timestamp":1792121416819,"version":"4.4.0"},"reference-count":170,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013479","type":"journal-article","created":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T10:28:45Z","timestamp":1574418525000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males"],"prefix":"10.1002","volume":"2019","author":[{"given":"Hanna","family":"Bergman","sequence":"first","affiliation":[{"name":"Cochrane; Cochrane Response; St Albans House 57-59 Haymarket London UK SW1Y 4QX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S","family":"Buckley","sequence":"additional","affiliation":[{"name":"Cochrane; Cochrane Response; St Albans House 57-59 Haymarket London UK SW1Y 4QX"},{"name":"University of Phillipines; Department of Surgery; Manila Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Villanueva","sequence":"additional","affiliation":[{"name":"Cochrane; Cochrane Response; St Albans House 57-59 Haymarket London UK SW1Y 4QX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Petkovic","sequence":"additional","affiliation":[{"name":"Cochrane; Cochrane Response; St Albans House 57-59 Haymarket London UK SW1Y 4QX"},{"name":"University of Ottawa; Bruy\u00e8re Research Institute; 43 Bruy\u00e8re St Annex E, room 312 Ottawa ON Canada K1N 5C8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantelle","family":"Garritty","sequence":"additional","affiliation":[{"name":"Cochrane; Cochrane Response; St Albans House 57-59 Haymarket London UK SW1Y 4QX"},{"name":"Ottawa Hospital Research Institute; Ottawa Methods Centre, Clinical Epidemiology Program; Ottawa Ontario Canada K1H 8L1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Lutje","sequence":"additional","affiliation":[{"name":"Liverpool School of Tropical Medicine; Department of Clinical Sciences; Pembroke Place Liverpool UK L3 5QA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina Ximena","family":"Riveros-Balta","sequence":"additional","affiliation":[{"name":"World Health Organization; Initiative for Vaccine Research; Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Low","sequence":"additional","affiliation":[{"name":"University of Bern; Institute of Social and Preventive Medicine (ISPM); Finkenhubelweg 11 Bern Switzerland CH-3012"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Henschke","sequence":"additional","affiliation":[{"name":"Cochrane; Cochrane Response; St Albans House 57-59 Haymarket London UK SW1Y 4QX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,11,22]]},"reference":[{"issue":"48","key":"10.1002\/14651858.CD013479-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"5745","DOI":"10.1016\/j.vaccine.2013.09.032","article-title":"Safety and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo controlled study","volume":"31","author":"Denny","year":"2013","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD013479-BIB0002|cit2","unstructured":"GSK 107863 (HPV-020 PRI) Evaluation of the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV vaccine 580299 (Cervarix TM) in adult human immunodeficiency virus (HIV) infected female subjects www.gsk-clinicalstudyregister.com\/files2\/gsk-107863-clinical-study-report2-redact.pdf"},{"key":"10.1002\/14651858.CD013479-BIB0003|cit3","unstructured":"GlaxoSmithKline Evaluation of the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV vaccine 580299 (Cervarix TM) in adult human immunodeficiency virus (HIV) infected female subjects clinicaltrials.gov\/ct2\/show\/results\/NCT00586339"},{"key":"10.1002\/14651858.CD013479-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial","volume":"309","author":"Dobson","year":"2013","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD013479-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1128\/CVI.00489-10","article-title":"Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial","volume":"18","author":"Krajden","year":"2011","journal-title":"Clinical and Vaccine Immunology"},{"issue":"5","key":"10.1002\/14651858.CD013479-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.vaccine.2013.09.007","article-title":"Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, MerckcLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial","volume":"32","author":"Krajden","year":"2014","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD013479-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1001\/jama.2017.1840","article-title":"Immunogenicity of 2 vs 3 doses of the quadrivalent human papillomavirus vaccine in girls aged 9 to 13 years after 60 months","volume":"317","author":"Ogilvie","year":"2017","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD013479-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013479-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1128\/CVI.05208-11","article-title":"Immunogenicity of the quadrivalent human papillomavirus (type 6\/11\/16\/18) vaccine in males 16 to 26 years old","volume":"19","author":"Hillman","year":"2012","journal-title":"Clinical and Vaccine Immunology"},{"key":"10.1002\/14651858.CD013479-BIB0010|cit10","unstructured":"Merck Sharp Dohme An investigational vaccine in reducing the incidence of anogenital warts in young men clinicaltrials.gov\/ct2\/show\/results\/NCT00090285"},{"issue":"7","key":"10.1002\/14651858.CD013479-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"768","DOI":"10.4161\/hv.7.7.15579","article-title":"Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults","volume":"7","author":"Moreira","year":"2011","journal-title":"Human Vaccines"},{"key":"10.1002\/14651858.CD013479-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013479-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12981-017-0160-0","article-title":"Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM)","volume":"14","author":"Hidalgo-Tenorio","year":"2017","journal-title":"AIDS Research and Therapy"},{"key":"10.1002\/14651858.CD013479-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.2016.17615","article-title":"Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women","volume":"316","author":"Iversen","year":"2016","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD013479-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/01.ogx.0000520560.06951.a2","article-title":"Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women","volume":"72","author":"Iversen","year":"2017","journal-title":"Obstetrical and Gynecological Survey"},{"key":"10.1002\/14651858.CD013479-BIB0016|cit16","unstructured":"Merck Sharp Dohme Phase III study of a 2-dose regimen of a multivalent human papillomavirus (HPV) vaccine (V503), administered to 9 to 14 year-olds and compared to young women, 16 to 26 years old (V503-010) clinicaltrials.gov\/ct2\/show\/results\/NCT01984697"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD013479-BIB0017|cit17","first-page":"S9","article-title":"Effect of the 9vHPV vaccine on abnormal cytology and genital procedures related to HPV31\/33\/45\/52\/58","volume":"18","author":"Bouchard","year":"2014","journal-title":"Journal of Lower Genital Tract Disease"},{"issue":"1","key":"10.1002\/14651858.CD013479-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/1740774514552110","article-title":"A seamless phase IIB\/III adaptive outcome trial: design rationale and implementation challenges","volume":"12","author":"Chen","year":"2015","journal-title":"Clinical Trials Journal"},{"key":"10.1002\/14651858.CD013479-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1016\/j.vaccine.2017.07.017","article-title":"Antibody persistence and evidence of immune memory at 5 years following administration of the 9-valent HPV vaccine","volume":"35","author":"Guevara","year":"2017","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD013479-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/S0140-6736(17)31821-4","article-title":"Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial","volume":"390","author":"Huh","year":"2017","journal-title":"Lancet"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD013479-BIB0021|cit21","first-page":"S10","article-title":"End of study efficacy for vulvovaginal disease of a novel 9-valent HPV L1 virus-like particle vaccine in 16-26 year old women","volume":"19","author":"Joura","year":"2015","journal-title":"Journal of Lower Genital Tract Disease"},{"key":"10.1002\/14651858.CD013479-BIB0022|cit22","first-page":"174","article-title":"End of study efficacy and immunogenicity of a novel 9-valent HPV L1 virus-like particle vaccine in 16-26 year old women","volume":"OC6","author":"Joura","year":"2015","journal-title":"EUROGIN 2015 Abstracts: HPV Infection and Related Cancers"},{"issue":"9","key":"10.1002\/14651858.CD013479-BIB0023|cit23","first-page":"S4:32","article-title":"Efficacy of a novel 9-valent HPV vaccine against high-grade lesions and cancer in 16-to 26-year-old women","volume":"24","author":"Joura","year":"2014","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD013479-BIB0025|cit24","first-page":"35","article-title":"Clinical efficacy and immunogenicity of the nonavalent HPV vaccine","volume":"60","author":"Joura","year":"2016","journal-title":"Acta Cytologica"},{"key":"10.1002\/14651858.CD013479-BIB0024|cit25","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013479-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cct.2015.02.009","article-title":"Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine","volume":"42","author":"Luxembourg","year":"2015","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.CD013479-BIB0027|cit27","first-page":"E270","article-title":"End of study efficacy, immunogenicity and safety of a novel 9-valent HPV l1 virus-like particle vaccine in 16-26 year old women","volume":"131 Suppl 5","author":"Mayrand","year":"2015","journal-title":"International Journal of Gynecology and Obstetrics"},{"key":"10.1002\/14651858.CD013479-BIB0028|cit28","unstructured":"Merck Sharp Dohme A randomized, international, double-blinded (with in-house blinding), controlled with gardasil, dose-ranging, tolerability, immunogenicity, and efficacy study of a multivalent human papillomavirus (HPV) L1 virus-like particle (VLP) vaccine administered to 16- to 26- year-old women clinicaltrials.gov\/ct2\/show\/results\/NCT00543543"},{"key":"10.1002\/14651858.CD013479-BIB0029|cit29","unstructured":"GSK 106636 (HPV-040 PRI) Evaluation of the effectiveness of two vaccination strategies using GlaxoSmithKline Biologicals\u2019 HPV vaccine GSK580299 administered in healthy adolescents www.gsk-clinicalstudyregister.com\/study\/106636?search=study&search_terms=106636#csr"},{"issue":"10","key":"10.1002\/14651858.CD013479-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.vaccine.2014.12.019","article-title":"Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial","volume":"33","author":"Lehtinen","year":"2015","journal-title":"Vaccine"},{"issue":"12","key":"10.1002\/14651858.CD013479-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1080\/21645515.2016.1183847","article-title":"Safety of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: interim analysis of a large community-randomized controlled trial","volume":"12","author":"Lehtinen","year":"2016","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"5","key":"10.1002\/14651858.CD013479-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/ijc.31119","article-title":"Impact of gender-neutral or girls-only vaccination against human papillomavirus - results of a community-randomized clinical trial (I)","volume":"142","author":"Lehtinen","year":"2018","journal-title":"International Journal of Cancer"},{"key":"10.1002\/14651858.CD013479-BIB0033|cit33","unstructured":"NCT00534638 Effectiveness, safety and immunogenicity of GSK Biologicals' HPV vaccine GSK580299 (Cervarix TM) administered in healthy adolescents clinicaltrials.gov\/ct2\/show\/results\/NCT00534638"},{"key":"10.1002\/14651858.CD013479-BIB0034|cit34","unstructured":"GSK 115411 (HPV-071 PRI) Immunogenicity and safety study of GlaxoSmithKline Biologicals' HPV-16\/18 L1 AS04 vaccine and Merck's Gardasil\u00ae vaccine when administered according to alternative 2-dose schedules in 9-14 year old females www.gsk-clinicalstudyregister.com\/files2\/gsk-115411-clinical-study-report-redact.pdf"},{"key":"10.1002\/14651858.CD013479-BIB0035|cit35","unstructured":"GlaxoSmithKline Immunogenicity and safety study of GlaxoSmithKline Biologicals' HPV-16\/18 L1 AS04 vaccine and Merck's Gardasil\u00ae vaccine when administered according to alternative 2-dose schedules in 9-14 year old females clinicaltrials.gov\/ct2\/show\/results\/NCT01462357"},{"key":"10.1002\/14651858.CD013479-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1080\/21645515.2015.1050570","article-title":"Comparative immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine administered according to 2-and 3-dose schedules in girls aged 9-14 years: results to month 12 from a randomized trial","volume":"11","author":"Leung","year":"2015","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"10.1002\/14651858.CD013479-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.vaccine.2017.11.034","article-title":"Comparative immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: results to month 36 from a randomized trial","volume":"36","author":"Leung","year":"2018","journal-title":"Vaccine"},{"issue":"13","key":"10.1002\/14651858.CD013479-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.vaccine.2017.02.021","article-title":"Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: effect of a fourth dose of vaccine","volume":"35","author":"Levin","year":"2018","journal-title":"Vaccine"},{"issue":"2","key":"10.1002\/14651858.CD013479-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/QAI.0b013e3181de8d26","article-title":"Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old","volume":"55","author":"Levin","year":"2010","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"issue":"8","key":"10.1002\/14651858.CD013479-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1093\/infdis\/jis489","article-title":"Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children","volume":"206","author":"Weinberg","year":"2012","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD013479-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.vaccine.2013.11.098","article-title":"Randomized controlled trial of two dosing schedules for human papillomavirus vaccination among college age males","volume":"32","author":"Lin","year":"2014","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD013479-BIB0042|cit42","unstructured":"Merck Sharp Dohme Randomized trial of alternative HPV vaccination schedules in males in a university setting clinicaltrials.gov\/ct2\/show\/results\/NCT01184079"},{"key":"10.1002\/14651858.CD013479-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1080\/21645515.2016.1236880","article-title":"The effect of perceived psychological stress on the immunogenicity of the quadrivalent human papillomavirus vaccine in males","volume":"13","author":"Wu","year":"2017","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"10.1002\/14651858.CD013479-BIB0044|cit44","unstructured":"NCT00941889 The effect of HPV vaccination on recurrence rates in HIV patients with condylomata clinicaltrials.gov\/ct2\/show\/results\/NCT00941889?view=results"},{"key":"10.1002\/14651858.CD013479-BIB0045|cit45","unstructured":"GlaxoSmithKline Safety and immunogenicity of Cervarix\u2122 in human immunodeficiency virus infected females www.gsk-clinicalstudyregister.com\/files2\/109823-clinical-study-result-summary.pdf"},{"key":"10.1002\/14651858.CD013479-BIB0046|cit46","unstructured":"NCT01031069 Evaluation of safety and immunogenicity of a human papillomavirus (HPV) vaccine in human immunodeficiency virus (HIV) infected females clinicaltrials.gov\/ct2\/show\/NCT01031069"},{"key":"10.1002\/14651858.CD013479-BIB0047|cit47","unstructured":"NCT01862874 Efficacy and tolerability study of V501 in Japanese males (V501-122) clinicaltrials.gov\/ct2\/show\/NCT01862874"},{"key":"10.1002\/14651858.CD013479-BIB0048|cit48","unstructured":"GSK 580299\/011 (HPV-011) A phase I\/II, observer-blind, randomized, controlled study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals' HPV-16\/18 L1 VLP AS04 vaccine administered intramuscularly according to a 0, 1, 6 month schedule in healthy male subjects aged 10-18 years www.gsk-clinicalstudyregister.com\/files2\/gsk-580299-011-clinical-study-report-redact.pdf"},{"issue":"1","key":"10.1002\/14651858.CD013479-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jadohealth.2008.10.002","article-title":"Immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years","volume":"44","author":"Pet\u00e4j\u00e4","year":"2009","journal-title":"Journal of Adolescent Health"},{"key":"10.1002\/14651858.CD013479-BIB0050|cit50","unstructured":"GSK 114700 (HPV-070 PRI) Immunogenicity and safety study of GlaxoSmithKline Biologicals' HPV-16\/18 L1 AS04 vaccine when administered according to alternative 2-dose schedules in 9-14 year old females www.gsk-clinicalstudyregister.com\/files2\/gsk-114700-clinical-study-report-redact.pdf"},{"key":"10.1002\/14651858.CD013479-BIB0051|cit51","unstructured":"GlaxoSmithKline Immunogenicity and safety study of GlaxoSmithKline Biologicals' HPV-16\/18 L1 AS04 vaccine when administered according to alternative 2-dose schedules in 9-14 year old females clinicaltrials.gov\/ct2\/show\/results\/NCT01381575"},{"key":"10.1002\/14651858.CD013479-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/infdis\/jix154","article-title":"Sustained immunogenicity of 2-dose human papillomavirus 16\/18 AS04-adjuvanted vaccine schedules in girls aged 9-14 years: a randomized trial","volume":"215","author":"Huang","year":"2017","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD013479-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/infdis\/jiw036","article-title":"Randomized open trial comparing 2-dose regimens of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in girls aged 9-14 years versus a 3-dose regimen in women aged 15-25 years","volume":"214","author":"Puthanakit","year":"2016","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD013479-BIB0054|cit54","unstructured":"GSK 110659 (HPV-048 PRI) Evaluation of the safety and immunogenicity of GSK Biologicals' HPV vaccine 580299 when administered in healthy females aged 9-25 years using an alternative schedule and an alternative dosing as compared to the standard schedule and dosing www.gsk-clinicalstudyregister.com\/files2\/gsk-110659-clinical-study-report-redact.pdf"},{"key":"10.1002\/14651858.CD013479-BIB0055|cit55","unstructured":"GlaxoSmithKline Evaluation of the safety and immunogenicity of GSK Biologicals' HPV vaccine 580299 when administered in healthy females aged 9-25 years using an alternative schedule and an alternative dosing as compared to the standard schedule and dosing clinicaltrials.gov\/ct2\/show\/results\/NCT00541970"},{"key":"10.1002\/14651858.CD013479-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/21645515.2015.1065363","article-title":"Sustained immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modelling predictions from a randomized study","volume":"12","author":"Romanowski","year":"2016","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"10.1002\/14651858.CD013479-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.4161\/hv.28022","article-title":"Immune response to the HPV-16\/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study","volume":"10","author":"Romanowski","year":"2014","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"10.1002\/14651858.CD013479-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.4161\/hv.7.12.18322","article-title":"Immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study","volume":"7","author":"Romanowski","year":"2011","journal-title":"Human Vaccines"},{"issue":"13","key":"10.1002\/14651858.CD013479-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.vaccine.2016.02.019","article-title":"Human papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines","volume":"34","author":"Faust","year":"2016","journal-title":"Vaccine"},{"issue":"e-1","key":"10.1002\/14651858.CD013479-BIB0061|cit60","first-page":"174","article-title":"Immunogenicity and reactogenicity of Cervarix versus Gardasil in HIV-infected adults: an RCT","volume":"22","author":"Toft","year":"2014","journal-title":"Topics in Antiviral Medicine"},{"issue":"8","key":"10.1002\/14651858.CD013479-BIB0060|cit61","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/infdis\/jit657","article-title":"Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial","volume":"209","author":"Toft","year":"2014","journal-title":"Journal of Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD013479-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.4161\/hv.27925","article-title":"Comparison of the immunogenicity of Cervarix\u00ae and Gardasil\u00ae human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults","volume":"10","author":"Toft","year":"2014","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"10.1002\/14651858.CD013479-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1016\/j.vaccine.2016.06.056","article-title":"A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men","volume":"34","author":"Damme","year":"2016","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD013479-BIB0064|cit64","unstructured":"Merck Sharp Dohme A randomized, double-blinded, controlled with GARDASIL (human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed)), Phase III clinical trial to study the immunogenicity and tolerability of V503 (9-valent human papillomavirus (HPV) vaccine) in preadolescent and adolescent girls (9- to 15-year-old) clinicaltrials.gov\/ct2\/show\/results\/NCT01304498"},{"key":"10.1002\/14651858.CD013479-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/INF.0000000000000773","article-title":"A randomized, double-blind, phase III study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus Gardasil\u00ae in 9-15-year-old girls","volume":"34","author":"Vesikari","year":"2015","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD013479-BIB0066|cit66","first-page":"364","article-title":"Baseline data of a Phase 3 trial of the quadrivalent HPV vaccine in HIV+ males and females: ACTG 5298","volume":"22","author":"Cranston","year":"2014","journal-title":"Topics in Antiviral Medicine"},{"key":"10.1002\/14651858.CD013479-BIB0067|cit67","unstructured":"NCT01461096 Quadrivalent HPV vaccine to prevent anal HPV in HIV-infected men and women clinicaltrials.gov\/ct2\/show\/results\/NCT01461096"},{"key":"10.1002\/14651858.CD013479-BIB0068|cit68","first-page":"65","article-title":"ACTG A5298: a phase 3 trial of the quadrivalent HPV vaccine in older HIV+ adults","volume":"24(E-1)","author":"Wilkin","year":"2018","journal-title":"Topics in Antiviral Medicine"},{"issue":"9","key":"10.1002\/14651858.CD013479-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/cid\/ciy274","article-title":"A randomized, placebo-controlled trial of the quadrivalent HPV vaccine in HIV-infected adults age 27 years or older: AIDS Clinical Trials Group protocol A5298","volume":"67","author":"Wilkin","year":"2018","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD013479-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"djv302","DOI":"10.1093\/jnci\/djv302","article-title":"Multisite HPV16\/18 vaccine efficacy against cervical, anal, and oral HPV infection","volume":"108","author":"Beachler","year":"2016","journal-title":"Journal of the National Cancer Institute"},{"issue":"12","key":"10.1002\/14651858.CD013479-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1002\/ijc.30030","article-title":"Use of HPV testing for cervical screening in vaccinated women - insights from the SHEVa (Scottish HPV Prevalence in Vaccinated Women) study","volume":"138","author":"Bhatia","year":"2016","journal-title":"International Journal of Cancer"},{"issue":"6","key":"10.1002\/14651858.CD013479-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00404-016-4167-x","article-title":"Chlamydia trachomatis infection and HPV\/Chlamydia trachomatis coinfection among HPV-vaccinated young women at the beginning of their sexual activity","volume":"294","author":"Bianchi","year":"2016","journal-title":"Archives of Gynecology and Obstetrics"},{"issue":"13","key":"10.1002\/14651858.CD013479-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"2309-14","DOI":"10.1016\/j.vaccine.2012.01.058","article-title":"Randomized trial of HPV4 vaccine assessing the response to HPV4 vaccine in two schedules among Peruvian female sex workers","volume":"30","author":"Brown","year":"2012","journal-title":"Vaccine"},{"issue":"9","key":"10.1002\/14651858.CD013479-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"e1002388","DOI":"10.1371\/journal.pmed.1002388","article-title":"Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: results of the Compass pilot randomised trial","volume":"14","author":"Canfell","year":"2017","journal-title":"PLOS Medicine"},{"key":"10.1002\/14651858.CD013479-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jcv.2016.09.011","article-title":"Effectivenessof HPV vaccination in women reaching screening age in Italy","volume":"84","author":"Carozzi","year":"2016","journal-title":"Journal of Clinical Virology"},{"issue":"1","key":"10.1002\/14651858.CD013479-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jnma.2015.12.003","article-title":"Higher prevalence of human papillomavirus-related cervical precancerous abnormalities in HIV-infected compared to HIV-uninfected women","volume":"108","author":"Choudhury","year":"2016","journal-title":"Journal of the National Medical Association"},{"issue":"3","key":"10.1002\/14651858.CD013479-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1097\/INF.0b013e318206c26e","article-title":"Immunogenicity and safety of human papillomavirus-16\/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years: results from a randomized study","volume":"30","author":"Esposito","year":"2011","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"1","key":"10.1002\/14651858.CD013479-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2105\/AJPH.2017.304119","article-title":"Declines in anogenital warts among age groups most likely to be impacted by human papillomavirus vaccination, United States, 2006-2014","volume":"108","author":"Flagg","year":"2018","journal-title":"American Journal of Public Health"},{"issue":"12","key":"10.1002\/14651858.CD013479-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1002\/ijc.30391","article-title":"Prior human papillomavirus-16\/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: post-hoc analysis from a randomized controlled trial","volume":"139","author":"Garland","year":"2016","journal-title":"International Journal of Cancer"},{"issue":"3","key":"10.1002\/14651858.CD013479-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1080\/21645515.2015.1011570","article-title":"The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine","volume":"11","author":"Gilca","year":"2015","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"6","key":"10.1002\/14651858.CD013479-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/apm.12677","article-title":"The prevalence of HPV infections in HPV-vaccinated women from the general population","volume":"125","author":"Hamsikova","year":"2017","journal-title":"Apmis"},{"issue":"6","key":"10.1002\/14651858.CD013479-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/infdis\/jiv519","article-title":"Crossprotection of the bivalent human papillomavirus (HPV) vaccine against variants of genetically related high-risk HPV infections","volume":"213","author":"Harari","year":"2016","journal-title":"Journal of Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD013479-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2016.1277846","article-title":"Reactogenicity of Cervarix and Gardasil human papillomavirus (HPV) vaccines in a randomized single blind trial in healthy UK adolescent females","volume":"13","author":"Haskins-Coulter","year":"2017","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"8","key":"10.1002\/14651858.CD013479-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/infdis\/jit363","article-title":"Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose","volume":"208","author":"Lamontagne","year":"2013","journal-title":"Journal of Infectious Diseases"},{"issue":"8","key":"10.1002\/14651858.CD013479-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"e015867","DOI":"10.1136\/bmjopen-2017-015867","article-title":"Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials","volume":"7","author":"Lehtinen","year":"2017","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD013479-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.cct.2016.10.006","article-title":"Design of a long-term follow-up effectiveness, immunogenicity and safety study of women who received the 9-valent human papillomavirus vaccine","volume":"52","author":"Luxembourg","year":"2017","journal-title":"Contemporary Clinical Trials"},{"issue":"40","key":"10.1002\/14651858.CD013479-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1016\/j.vaccine.2016.08.016","article-title":"HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine","volume":"34","author":"Money","year":"2016","journal-title":"Vaccine"},{"issue":"14","key":"10.1002\/14651858.CD013479-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1001\/jama.2011.407","article-title":"Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial","volume":"305","author":"Neuzil","year":"2011","journal-title":"JAMA"},{"issue":"10","key":"10.1002\/14651858.CD013479-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S1473-3099(16)30120-7","article-title":"Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study","volume":"16","author":"Wheeler","year":"2016","journal-title":"Lancet Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD013479-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/cam4.869","article-title":"Efficacy, immunogenicity, and safety of the HPV-16\/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial","volume":"6","author":"Zhu","year":"2017","journal-title":"Cancer Medicine"},{"issue":"8","key":"10.1002\/14651858.CD013479-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1089\/jwh.2009.1753","article-title":"Randomized trial of an alternate human papillomavirus vaccine administration schedule in college-aged women","volume":"19","author":"Zimmerman","year":"2010","journal-title":"Journal of Women's Health"},{"issue":"11","key":"10.1002\/14651858.CD013479-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.vaccine.2018.02.006","article-title":"Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5\u202fyears of follow-up","volume":"36","author":"Huang","year":"2018","journal-title":"Vaccine"},{"issue":"28","key":"10.1002\/14651858.CD013479-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1016\/j.vaccine.2012.02.079","article-title":"Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double-blind, placebo-controlled trial in Chinese males and females","volume":"30","author":"Li","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"10.1002\/14651858.CD013479-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"e657","DOI":"10.1542\/peds.2013-4144","article-title":"Long-term study of a quadrivalent human papillomavirus vaccine","volume":"134","author":"Ferris","year":"2014","journal-title":"Pediatrics"},{"issue":"6","key":"10.1002\/14651858.CD013479-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"pii: e20163947","DOI":"10.1542\/peds.2016-3947","article-title":"4-Valent Human Papillomavirus (4vHPV) Vaccine in Preadolescents and Adolescents After 10 Years","volume":"140","author":"Ferris","year":"2017","journal-title":"Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD013479-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/01.inf.0000253970.29190.5a","article-title":"Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial","volume":"26","author":"Reisinger","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1002\/14651858.CD013479-BIB0097|cit97","unstructured":"NCT01735006 Efficacy and immunogenicity study of recombinant human papillomavirus bivalent (type 16\/18) vaccine clinicaltrials.gov\/ct2\/show\/NCT01735006"},{"key":"10.1002\/14651858.CD013479-BIB0098|cit98","unstructured":"NCT01824537 Transmission reduction and prevention with HPV vaccination (TRAP-HPV) study (TRAP-HPV) clinicaltrials.gov\/ct2\/show\/NCT01824537"},{"key":"10.1002\/14651858.CD013479-BIB0099|cit99","unstructured":"NCT02009800 ICI-VPH: impact of HPV immunisation schedules against HPV (ICI-VPH) clinicaltrials.gov\/ct2\/show\/NCT02009800"},{"key":"10.1002\/14651858.CD013479-BIB0100|cit100","unstructured":"NCT02087384 HPV (human papilloma virus) vaccination after treatment of anal intraepithelial neoplasia (AIN) (VACCAIN-P) clinicaltrials.gov\/ct2\/show\/NCT02087384"},{"key":"10.1002\/14651858.CD013479-BIB0101|cit101","unstructured":"NCT02405520 Safety and immunogenicity study of the recombinant human papillomavirus virus type 6\/11 bivalent vaccine clinicaltrials.gov\/ct2\/show\/NCT02405520"},{"key":"10.1002\/14651858.CD013479-BIB0102|cit102","unstructured":"NCT02562508 A bridging study of a recombinant human papillomavirus 16\/18 bivalent vaccine in preadolescent girls clinicaltrials.gov\/ct2\/show\/NCT02562508"},{"key":"10.1002\/14651858.CD013479-BIB0103|cit103","unstructured":"NCT02567955 Immunogenicity and safety of Gardasil-9 and Cervarix clinicaltrials.gov\/ct2\/show\/NCT02567955"},{"key":"10.1002\/14651858.CD013479-BIB0104|cit104","unstructured":"NCT02710851 Immunogenicity study of the recombinant human papillomavirus virus type 6\/11 bivalent vaccine clinicaltrials.gov\/ct2\/show\/NCT02710851"},{"key":"10.1002\/14651858.CD013479-BIB0105|cit105","unstructured":"NCT02733068 A phase III study of human papillomavirus (HPV)-16\/18 vaccine clinicaltrials.gov\/ct2\/show\/NCT02733068"},{"key":"10.1002\/14651858.CD013479-BIB0106|cit106","unstructured":"NCT02740777 Evaluating the 2-dose immunization schedule of human papillomavirus (HPV)-16\/18 in adolescent females clinicaltrials.gov\/ct2\/show\/NCT02740777"},{"key":"10.1002\/14651858.CD013479-BIB0107|cit107","unstructured":"NCT02750202 Effectiveness study of human papilloma virus (HPV) vaccines to prevent recurrence of genital warts (TheraVACCS) clinicaltrials.gov\/ct2\/show\/NCT02750202"},{"key":"10.1002\/14651858.CD013479-BIB0108|cit108","unstructured":"NCT02834637 A dose reduction immunobridging and safety study of two HPV vaccines in Tanzanian girls (DoRIS) clinicaltrials.gov\/ct2\/show\/NCT02834637"},{"key":"10.1002\/14651858.CD013479-BIB0109|cit109","unstructured":"NCT02888418 Safety and immunogenicity study of human papilloma virus vaccine in women aged 9 to 30 and men aged 9 to 17 clinicaltrials.gov\/ct2\/show\/NCT02888418"},{"key":"10.1002\/14651858.CD013479-BIB0110|cit110","unstructured":"NCT03180034 Scientific evaluation of one or two doses of the bivalent or nonavalent prophylactic HPV vaccines https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03180034 (accessed on 27 August 2018) 2017"},{"key":"10.1002\/14651858.CD013479-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cct.2018.02.010","article-title":"Design and statistical considerations for studies evaluating the efficacy of a single dose of the human papillomavirus (HPV) vaccine","volume":"68","author":"Sampson","year":"2018","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.CD013479-BIB0112|cit112","unstructured":"NCT03296397 Efficacy of quadrivalent HPV vaccine to prevent relapses of genital warts after initial therapeutic response (CONDYVAC) clinicaltrials.gov\/ct2\/show\/NCT03296397"},{"key":"10.1002\/14651858.CD013479-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1016\/j.ejca.2014.07.018","article-title":"Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples","volume":"50","author":"Alemany","year":"2014","journal-title":"European Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD013479-BIB0114|cit114","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009069.pub3","article-title":"Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors","author":"Arbyn","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD013479-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1542\/peds.2006-0461","article-title":"Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women","volume":"118","author":"Block","year":"2006","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD013479-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"h2016","DOI":"10.1136\/bmj.h2016","article-title":"Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis","volume":"350","author":"Bogaards","year":"2015","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013479-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0264-410X(02)00449-8","article-title":"The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI)","volume":"21","author":"Bonhoeffer","year":"2002","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD013479-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jcp.55.4.244","article-title":"The causal relation between human papillomavirus and cervical cancer","volume":"55","author":"Bosch","year":"2002","journal-title":"Journal of Clinical Pathology"},{"issue":"4","key":"10.1002\/14651858.CD013479-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","article-title":"A review of human carcinogens--Part B: biological agents","volume":"10","author":"Bouvard","year":"2009","journal-title":"Lancet Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013479-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/sim.2528","article-title":"Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events","volume":"26","author":"Bradburn","year":"2007","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD013479-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bpobgyn.2017.08.010","article-title":"Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage","volume":"47","author":"Brotherton","year":"2018","journal-title":"Best Practice & Research. Clinical Obstetrics & Gynaecology"},{"issue":"12","key":"10.1002\/14651858.CD013479-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1086\/657321","article-title":"Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings","volume":"202","author":"Bruni","year":"2010","journal-title":"The Journal of Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD013479-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"Martel","year":"2017","journal-title":"International Journal of Cancer"},{"key":"10.1002\/14651858.CD013479-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"Sanjose","year":"2010","journal-title":"Lancet Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013479-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"9","key":"10.1002\/14651858.CD013479-BIB0126|cit126","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012805","article-title":"Aluminium adjuvants used in vaccines versus placebo or no intervention","author":"Djurisic","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013479-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jinf.2015.02.005","article-title":"Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: a systematic review and meta-analysis","volume":"71","author":"Donken","year":"2015","journal-title":"Journal of Infection"},{"issue":"19","key":"10.1002\/14651858.CD013479-BIB0128|cit128","first-page":"30298","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"pii: S0140-6736","author":"Drolet","year":"2019","journal-title":"Lancet"},{"issue":"32 Pt A","key":"10.1002\/14651858.CD013479-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1016\/j.vaccine.2018.02.003","article-title":"Status of HPV vaccine introduction and barriers to country uptake","volume":"36","author":"Gallagher","year":"2018","journal-title":"Vaccine"},{"issue":"29","key":"10.1002\/14651858.CD013479-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1200\/JCO.2015.61.6995","article-title":"Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma","volume":"33","author":"Gillison","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013479-BIB0131|cit131","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2015"},{"key":"10.1002\/14651858.CD013479-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1128\/jcm.33.8.2058-2063.1995","article-title":"Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts","volume":"33","author":"Greer","year":"1995","journal-title":"Journal of Clinical Microbiology"},{"issue":"4","key":"10.1002\/14651858.CD013479-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","article-title":"GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias)","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD013479-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","article-title":"GRADE guidelines: 7. Rating the quality of evidence-inconsistency","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD013479-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","article-title":"GRADE guidelines: 5. Rating the quality of evidence - publication bias","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD013479-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013479-BIB0137|cit137","unstructured":"Higgins JP Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD013479-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013479-BIB0139|cit139","unstructured":"Higgins JP Altman DG Sterne JA editor(s) Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), The Cochrane Collaboration, 2017 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013479-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41541-018-0089-x","article-title":"Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want","volume":"3","author":"HogenEsch","year":"2018","journal-title":"npj Vaccines"},{"key":"10.1002\/14651858.CD013479-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/pds.2208","article-title":"Pitfalls in meta-analyses on adverse events reported from clinical trials","volume":"20","author":"Huang","year":"2011","journal-title":"Pharmacoepidemiology and drug safety"},{"key":"10.1002\/14651858.CD013479-BIB0142|cit142","volume-title":"Primary End-points for Prophylactic HPV Vaccine Trials. IARC Working Group Report","author":"International Agency for Research in Cancer","year":"2014"},{"issue":"10","key":"10.1002\/14651858.CD013479-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"781","DOI":"10.7326\/0003-4819-141-10-200411160-00009","article-title":"Better reporting of harms in randomized trials: an extension of the CONSORT statement","volume":"141","author":"Ioannidis","year":"2004","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013479-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S1473-3099(04)00927-2","article-title":"Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence","volume":"4","author":"Jefferson","year":"2004","journal-title":"Lancet Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD013479-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13643-018-0675-z","article-title":"Index of the human papillomavirus (HPV) vaccine industry clinical study programmes and non-industry funded studies: a necessary basis to address reporting bias in a systematic review","volume":"7","author":"J\u00f8rgensen","year":"2018","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD013479-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/bmjebm-2018-111012","article-title":"The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias","volume":"23","author":"J\u00f8rgensen","year":"2018","journal-title":"BMJ Evidence-Based Medicine"},{"issue":"19","key":"10.1002\/14651858.CD013479-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/jnci\/djr319","article-title":"Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine","volume":"103","author":"Kreimer","year":"2011","journal-title":"Journal of the National Cancer Institute"},{"issue":"7","key":"10.1002\/14651858.CD013479-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1470-2045(15)00047-9","article-title":"Efficacy of fewer than three doses of an HPV-16\/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials","volume":"16","author":"Kreimer","year":"2015","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD013479-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1365-2613.2008.00636.x","article-title":"Histological characteristics of human papilloma-virus-positive and-negative invasive and in situ squamous cell tumours of the penis","volume":"90","author":"Krustrup","year":"2009","journal-title":"International Journal of Experimental Pathology"},{"key":"10.1002\/14651858.CD013479-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ijgo.12186","article-title":"Progress in HPV vaccination in low- and lower-middle-income countries","volume":"138","author":"LaMontagne","year":"2017","journal-title":"International Journal of Gynecology & Obstetrics"},{"key":"10.1002\/14651858.CD013479-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"i5078","DOI":"10.1136\/bmj.i5078","article-title":"Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry\/journal editor perspective","volume":"355","author":"Lineberry","year":"2016","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD013479-BIB0152|cit152","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub3","article-title":"Industry sponsorship and research outcome","author":"Lundh","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"32 Pt A","key":"10.1002\/14651858.CD013479-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1016\/j.vaccine.2018.01.057","article-title":"Human papillomavirus vaccine effectiveness by number of doses: systematic review of data from national immunization programs","volume":"36","author":"Markowitz","year":"2018","journal-title":"Vaccine"},{"issue":"5","key":"10.1002\/14651858.CD013479-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(08)70103-7","article-title":"Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study","volume":"9","author":"McCredie","year":"2008","journal-title":"Lancet Oncology"},{"issue":"9580","key":"10.1002\/14651858.CD013479-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013479-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1001\/jama.2012.87802","article-title":"Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement.","volume":"308","author":"Piaggio","year":"2012","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD013479-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(15)00414-3","article-title":"Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study","volume":"17","author":"Sankaranarayanan","year":"2016","journal-title":"Lancet Oncology"},{"issue":"32 Pt A","key":"10.1002\/14651858.CD013479-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1016\/j.vaccine.2017.12.079","article-title":"Explanations for the high potency of HPV prophylactic vaccines","volume":"36","author":"Schiller","year":"2018","journal-title":"Vaccine"},{"issue":"3","key":"10.1002\/14651858.CD013479-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s11904-014-0224-x","article-title":"HPV and anal cancer in HIV-infected individuals: a review","volume":"11","author":"Schim van der Loeff","year":"2014","journal-title":"Current HIV\/AIDS Reports"},{"key":"10.1002\/14651858.CD013479-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jclinepi.2017.07.006","article-title":"The Yusuf-Peto method was not a robust method for meta-analyses of rare events data from antidepressant trials","volume":"91","author":"Sharma","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013479-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"9112","DOI":"10.1016\/j.vaccine.2011.02.091","article-title":"The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia","volume":"29","author":"Smith","year":"2011","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD013479-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/rmv.498","article-title":"Human papillomavirus vaccines","volume":"16","author":"Stanley","year":"2006","journal-title":"Reviews in Medical Virology"},{"key":"10.1002\/14651858.CD013479-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1586\/14760584.2014.935767","article-title":"Alternative dosage schedules with HPV virus-like particle vaccines","volume":"13","author":"Stanley","year":"2014","journal-title":"Expert Review of Vaccines"},{"key":"10.1002\/14651858.CD013479-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/OLQ.0b013e31827aa9b3","article-title":"Human papillomavirus typing in reporting of Condyloma","volume":"40","author":"Sturegard","year":"2013","journal-title":"Sexually Transmitted Diseases"},{"key":"10.1002\/14651858.CD013479-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/annonc\/mdq454","article-title":"The role of human papillomavirus infection in head and neck cancers","volume":"21","author":"Syrj\u00e4nen","year":"2010","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013479-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/infdis\/jiq015","article-title":"External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents","volume":"203","author":"Vardas","year":"2011","journal-title":"Journal of Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD013479-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"e20153863","DOI":"10.1542\/peds.2015-3863","article-title":"Interventions to improve HPV vaccine uptake: a systematic review","volume":"138","author":"Walling","year":"2016","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD013479-BIB0168|cit168","first-page":"241","article-title":"Human papillomavirus vaccines: WHO position paper, May 2017","volume":"92","author":"World Health Organization","year":"2017","journal-title":"Weekly Epidemiological Record"},{"key":"10.1002\/14651858.CD013479-BIB0169|cit169","unstructured":"Bergman H Henschke N Buckley B Villanueva G Petkovic J Garritty C Protocol for an update of a systematic review and meta-analysis of the immunogenicity and efficacy of HPV vaccines in females and males aged 9-26 years osf.io\/qchzb"},{"key":"10.1002\/14651858.CD013479-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1016\/j.vaccine.2017.03.096","article-title":"Two-dose schedules for human papillomavirus vaccine: systematic review and meta-analysis","volume":"35","author":"D'Addario","year":"2017","journal-title":"Vaccine"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD013479\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T10:48:50Z","timestamp":1693478930000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013479"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,11,22]]},"references-count":170,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013479","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,22]]}}}